The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …

Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …

Background: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2
inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of …

Objective The objective is to formulate clinical practice guidelines for the treatment of
diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …